

Form PTO-1595 (Rev. 06/04)

U.S. DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET  
PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office. Please record the attached documents or the address(es) below..

1. Name of conveying party(ies)/Execution Date(s):

CV Technologies, Inc.

Execution Date(s): September 11, 2006

Additional name(s) of conveying party(ies) attached?  
attached?  Yes  No

2. Name and address of receiving party(ies):

NAME: fX Life Sciences International GmbH

ADDRESS: Baarerstrasse 135  
6301 Zug, Switzerland

3. Name of Conveyance:

- Assignment  Merger
- Security Agreement  Change of Name
- Government Interest Assignment
- Executive Order 9424, Confirmatory License
- Other

Additional name(s) & addresses(es) attached?  
 Yes  No

4. Application number(s) or patent number(s):  This document is being filed together with a new application

A. Patent Application No.(s)

SEE ATTACHED SCHEDULE B

B. Patent No.(s)

SEE ATTACHED SCHEDULE B

Additional numbers attached?  Yes  No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name:  
Address: Rothwell, Figg, Ernst & Manbeck  
Suite 800  
Street Address: 1425 K St., N.W.  
City: Washington,  
State: D.C. Zip: 20005  
Telephone No.: 202/783-6040  
Facsimile No.: 202/783-6031  
Email Address:  
Attorney Docket No. : 2968-000

6. Total number of applications and patents involved: 11

7. Total fee (37 CFR 3.41): . . . . \$ 440


- Enclosed
- Authorized to be charged to deposit account
- None required (government interest not affecting title)

8. Deposit account number: 02-2135

Authorized User Name Robert B. Murray

DO NOT USE THIS SPACE

9. Signature.



Signature

October 23, 2006  
Date

Robert B. Murray

Name of Person Signing

Total number of pages including cover sheet, attachments and documents: 8

**SCHEDULE B**

<b>U.S. Patent/U.S. Application</b>		<b>Issue Date/Filed Date</b>
1.	5,739,274	April 14, 1998
2.	6,083,932	July 4, 2000
3.	6,060,516	May 9, 2000
4.	6,156,291	December 5, 2000
5.	6,432,454	August 13, 2002
6.	6,593,340	July 15, 2003
7.	7,067,160	June 27, 2006
8.	09/481,572	January 11, 2000
9.	10/690,628	October 23, 2003
10.	10/852,661	April 16, 2004
11.	11/114,089	April 26, 2005

1353915

## PATENT ASSIGNMENT

WHEREAS, CV Technologies, Inc. (hereinafter ASSIGNOR) a company having its principal office and place of business at 9411-20<sup>th</sup> avenue, Edmonton, AB T6N 1E5, Canada owns inventions reflected by the patent applications and patents on the attached Schedule A.

AND, WHEREAS, fX Life Sciences International GmbH (hereinafter ASSIGNEE), a company having its principal office and place of business at Baarerstrasse 135  
6301 Zug, Switzerland, is desirous of acquiring all right, title and interest therein.

NOW, THEREFORE, in consideration of the amounts specified in an Intellectual Property Purchase Agreement between the parties and executed of even date herewith, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the above said ASSIGNOR by these presents does sell, assign and transfer unto the said ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest in and to the said inventions and in and to the patent applications and patents on the said Schedule A, and all Letters Patent to be obtained therefore from any applications filed in any country, including the right to file applications under the provisions of any convention or treaty; and in and to any continuation, division, renewal, substitute, reissue, or reexamination in any country and in and to any patents, certificates, utility models, reissues, extensions, additions or confirmations thereof which may be granted in any country to have and to hold the same for its own use and benefit and for the use and benefit of its successors, assigns or legal representatives for the full term or terms for which the same may be granted. Notwithstanding the above, the parties hereto agree that this assignment document does not grant any rights to any Canadian patent applications or patents directed to the inventions otherwise assigned herein.

ASSIGNOR covenants that it has the full right to convey the entire right, title and interest herein assigned, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale.

ASSIGNOR agrees to execute all papers, take all rightful oaths and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said inventions in any and all countries and for vesting title thereto in said ASSIGNEE, its successors, assigns and legal representatives and also to execute separate assignments in connection with such applications as the ASSIGNEE may deem necessary or expedient to more effectually secure to and vest in ASSIGNEE its successors and assigns, the entire right, title and interest in and to said invention, application(s), patent rights, titles, benefits, privileges, and advantages hereby sold, assigned, confirmed, transferred and conveyed.

ASSIGNOR agrees to execute all papers in connection with any interference, litigation, or other legal proceeding which may be declared concerning each such application or any continuation, division, reissue or reexamination thereof or Letters Patent or reissue patent issued thereon and to cooperate with the ASSIGNEE in every way possible in obtaining and producing evidence and proceeding with such interference, litigation, or other legal proceeding involving same.

ASSIGNOR hereby authorizes and empowers the ASSIGNEE, its successors, assigns and legal representatives, to invoke and claim for any application for patent or other form of protection for said inventions the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which

PATENT

REEL: 018420 FRAME: 0327

may henceforth be substituted for it, and to invoke and claim such right of priority without further written or oral authorization from ASSIGNOR.

ASSIGNOR consents that a copy of this assignment shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be required in any country for any purpose and more particularly in proof of the right of the ASSIGNEE or nominee to claim the aforesaid benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it.

Notary

CV Technologies, Inc. (Assignor)



MARY JANE McKAY-CAREY  
BARRISTER & SOLICITOR

September 11, 2006

By: 

Typed Name: Lei Ling

Title: VP, Product Development

Date: Sept. 11, 2006


Notary

Accepted by fX Life Sciences International GmbH



MARY JANE McKAY-CAREY  
BARRISTER & SOLICITOR

September 11, 2006

By: 

Typed Name: Anja Atchison

Title: Controller

Date: Sept 11 / 06

## SCHEDULE A

## PATENTS

Compound	Title	Country	Type of Patent/ countries designated	Application #	Filing date	Filing Date (of non- prov parent patent)	Status	Issue date	Patent #
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	US	utility	09/581161	27-Jul-00	11-Dec-98	Granted	13-Aug-02	6 432 454 B1
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	US	Divisional	10/187,289; US 2003-0124207	2-Jul-02	11-Dec-98	Granted	27-Jun-06	7 067 160
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	US	Divisional	11/114,089; 20050196471	26-Apr-05	11-Dec-98	published		
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	US	continuation	10/690628; 2004/0137087	Oct. 23, 2003	11-Dec-98	Published		
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	New Zealand		504975	Dec. 11, 1998		Granted	June 08, 2004	504975
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	Australian		1903499	Dec. 11, 1998		granted	January 16th, 2003	752702
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	China		98812069	Dec. 11, 1998		Published		
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	European	AT, BE, CH, DE, DK, FI, FR, GB, IT,	98863784.8 (1998 963784) or EP1037645	Dec. 11, 1998		Published		

PATENT

Compound	Title	Country	Type of Patent/ countries designated	Application #	Filing date	Filing Date (of non- prov parent patent)	Status	Issue date	Patent #
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	Korea		10-7006333	Dec. 11, 1998				
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	Japan		2000-538705	Dec. 11, 1998		published		
CVT-E002	Process of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators	Hong Kong		1103080.2	Dec. 11, 1998		published		
CVT-E002	Treatment of autoimmune diseases with American ginseng extract	European	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE	913318.2 or 2000913318.2 or EP1161254	Feb. 25, 2000		Published		
HT1001	Pharmaceutical Compositions Derived from Ginseng and Methods of Treatment Using the Same	US		# 09/061961	17-Apr-98		granted	4-Jul-00	6083932
Hypericin (SjW)	Hypericin and hypericin extract specific T-type calcium channel blocker, and Their Use as T-Type Calcium Channel Targeted Therapeutics	US		09/481,572	11-Jan-00		published		
Hypericin (SjW)	Hypericin and hypericin extract specific T-type calcium channel blocker, and Their Use as T-Type Calcium Channel Targeted Therapeutics	China		99808429.8	9-Jul-99		published		
Hypericin (SjW)	Hypericin and hypericin extract specific T-type calcium channel blocker, and Their Use as T-Type Calcium Channel Targeted Therapeutics	European	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE	99933542.5 or 1999933542 or EP1094712	9-Jul-99		published		

PATENT

REEL: 018420 FRAME: 0330

Compound	Title	Country	Type of Patent/ countries designated	Application #	Filing date	Filing Date (of non- parent patent)	Status	Issue date	Patent #
Hypericin (SJW)	Hypericin and hypericin extract: specific T-type calcium channel blocker, and Their Use as T-Type Calcium Channel Targeted Therapeutics	Hong Kong		1107554.2	9-Jul-99		published		
Hypericin (SJW)	Hypericin and hypericin extract: specific T-type calcium channel blocker, and Their Use as T-Type Calcium Channel Targeted Therapeutics	Korea		2001-7000390	9-Jul-99		published		
Shark Cartilage	A Preparation Derived from Shark Cartilage for Treatment of Disease Related to Excessive PHF or Excessive Intracellular Calcium	china		98807088. X	9-Jul-98		published		
Shark Cartilage	A Preparation Derived from Shark Cartilage for Treatment of Disease Related to Excessive PHF or Excessive Intracellular Calcium	Hong Kong		105858	9-Jul-98		published		
Shark Cartilage	A Preparation Derived from Shark Cartilage for Treatment of Disease Related to Excessive PHF or Excessive Intracellular Calcium	Japan		2000-502067	9-Jul-98		published		
Shark Cartilage	A Preparation Derived from Shark Cartilage for Treatment of Disease Related to Excessive PHF or Excessive Intracellular Calcium	Korea		10-2000-7000327	9-Jul-98		published		
Shark Cartilage	A Preparation Derived from Shark Cartilage for Treatment of Disease Related to Excessive PHF or Excessive Intracellular Calcium	US	continuation	10/862661	16-Apr-04	11-Jul-97	published		
Shark Cartilage	A Preparation Derived from Shark Cartilage for Treatment of Disease Related to Excessive PHF or Excessive Intracellular Calcium	Australian	Divisional	2002325426	9-Jul-98		Granted	March 23, 2006 (acceptance notice)	2002325426

PATENT

REEL: 018420 FRAME: 0331

Compound	Title	Country	Type of Patent/ countries designated	Application #	Filing date	Filing Date (of non- prov parent patent)	Status	Issue date	Patent #
CHEMBIOPRINT	Chemical and Pharmacological Standardization of Herbal Extracts	European	AT, CH, DE, FI, FR, GB, IT, LI	98942181.3 or 1998942181 or EP10066802	Aug. 28, 1998		published		
CHEMBIOPRINT	Chemical and Pharmacological Standardization of Herbal Extracts	japan		2000-507241	Aug. 28, 1998		published		
CHEMBIOPRINT	Chemical and Pharmacological Standardization of Herbal Extracts	US		09/143361	Aug. 28, 1998		granted	Dec. 05, 2000	6156291
Synthetic Compound	N1-Propargylhydrazines.....	US		09/024113	Feb. 17, 1998		granted	9-May-00	6060516
Synthetic Compound	Pharmaceutical Compositions Containing N-Propargylphenethylamine and Related Analogues to Treat Neurodegeneration and/or Depression	US		09/794058	Feb. 28, 2001		granted	15-Jul-03	6593340
PHF	Active Component of Parathyroid Hypertensive Factor	US		08/387820	24-Feb-95		granted	14-Apr-98	5739274
AD-FX/Menta- FX/HT1001	ANTIOXIDANT AND FE2+ CHELATING PROPERTIES OF HERBAL EXTRACTS	US	Provisional	60/728,747	Oct 21, 2005		not published		



**ROTHWELL, FIGG, ERNST & MANBECK**

1425 K Street, NW  
Suite 800  
Washington, D.C. 20005

Telephone: (202)783-6040  
Telefax: (202)783-6031

**FACSIMILE TRANSMITTAL SHEET**

DATE: October 16, 2006

TO: The U. S. Patent and Trademark Office  
Attn: Assignment Branch

Fax. No.: 571 273 0140

Our Ref.: 2968-0000

FROM: Robert B. Murray

Number of Pages Including This Transmittal Sheet: 9

If any problems in connection with this facsimile, please contact: Cindy 202-624-1584

THIS MESSAGE IS INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR THE EMPLOYEE OR AGENCY RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICES. THANK YOU.

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this document is being transmitted by facsimile to the Assignment Branch of the The United States Patent and Trademark office, telefax number 571 273 0140 on this date of my signature.

Date: 10/23/06

CK Brooks